Dr. Nancy Chang, joined OrbiMed in 2007 as a Managing Director, Asia. Dr. Chang was the Co-Founder, CEO and Chairman of Tanox, Inc. She brings over 25 years of excellence in pioneering scientific research and entrepreneurial success to OrbiMed. Dr. Chang built Tanox from an idea to a substantial publicly-traded company which was acquired by Genentech in August 2007 for $919 Million. Tanox's initial public offering in 2000 was the second largest IPO ever for a biotechnology company at that time. During her career, Dr. Chang has received numerous awards for her leadership, including the Most Respected Woman in Biotechnology (MedAd News, 2005), Global Business Achievement Hall of Fame Governor's Award (2005), Texas Science Hall of Fame (2001), and Houston Entrepreneur of the Year (2000). Dr. Chang serves on the Boards of Directors of the Federal Reserve Bank in Houston, Charles River Laboratories, and she is also a member of the Board of Visitors at M. D. Anderson Cancer Center. Before launching Tanox, Dr. Chang served as Director of Research at Centocor, Inc. She received her Ph.D. in Biological Chemistry from Harvard University.

Back to Top

Dr. Jonathan Wang, joined OrbiMed in 2007 as a Managing Director, Asia. Dr. Wang has nearly 20 years experience in the life sciences field, most recently as General Manager of Burrill & Company's Greater China Group. Prior to Burrill, Dr. Wang worked for WI Harper Group and Walden International, both ranked among the leading global venture capital firms operating in Asia. At WI Harper, Dr. Wang was a Managing Director, overseeing the firm's life sciences activities worldwide. During this time he co-founded Bridge Pharmaceuticals, a pioneering cross-Pacific pharmaceutical R&D services company. Dr. Wang is Co-Founder and former Chairman of The BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. Dr. Wang also earned an M.B.A. from Stanford University.

Back to Top

Dr. Sunny Sharma, joined OrbiMed in 2008 as a Private Equity Partner, Asia. Dr. Sharma has more than 10 years of life sciences experience spanning venture capital, investment banking, and clinical practice. Dr. Sharma was most recently a Vice President at Investor Growth Capital (IGC), the wholly owned global venture capital arm of Investor AB. Previously he was a Managing Director at Easton Capital, a venture capital fund in New York. While at IGC and Easton Capital, Dr. Sharma led or played a senior role on over a dozen life sciences investments including Acorda (ACOR), CombinatoRx (CRXX), Morphotek (acquired by Eisai), Protez (acquired by Novartis), Salmedix (acquired by Cephalon) and Targacept (TRGT). Earlier in his career, Dr. Sharma was with Lehman Brothers' healthcare investment banking group in London, and before that he practiced medicine in northern India. Dr. Sharma holds an M.B.A. from Indian Institute of Management, Bangalore and a medical degree (M.B.B.S.) from Christian Medical College, Ludhiana where he was awarded the Vipin Khanna Memorial Gold Medal for graduating as the best intern.

Back to Top